thymidine/vēzis

Saite tiek saglabāta starpliktuvē

Izvēlieties kārtošanas veidu

Lappuse 1 no 59 rezultātiem

Treatment of cancer with thymidine in combination with temozolamide

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND OF THE INVENTION Temozolamide is the first drug approved by the United States Food and Drug Administration in over 50 years for the treatment of brain tumors. It is an imidazole tetrazinone compound and has demonstrated clinical efficacy in the treatment of high grade gliomas and

Cancer chemotherapy employing halogenated analogs of thymidine

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND Technical Field This disclosure relates to the field of chemotherapy treatment of patients having neoplastic disease. In particular, this disclosure relates to chemotherapy employing halogenated analogs of thymidine (abbreviated "HAT"). Background Information A. Pain Cancer-related pain,

Anti-cancer activity of an anti-thymidine kinase monoclonal antibody

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND OF THE INVENTION 1. Field of the Invention Embodiments of the invention relate to treatment of cancer with a monoclonal antibody to an S-phase regulated specific protein, particularly thymidine kinase. 2. Description of the Related Art The S-phase is the portion of the cell cycle during

Targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

The present application claims the priority of Chinese patent application No. 201210394006.2, filed on 10, Oct., 2012, to the Patent Office of the People's Republic of China, and titled "Targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof",

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 23, 2017, is named 11000_005154-WO0_SL.txt and is 2,658 bytes in size. FIELD OF THE

Monoclonal antibodies to human thymidine kinase to treat cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND 1. The Field of the Invention The invention relates to treatment of cancer and viral infections and more particularly to therapies using a monoclonal antibody to thymidine kinase. 2. The Background Art Thymidine kinase (ATP:thymidine-5' phosphotransferase; EC 2.7.1.21 in the International

Method for identifying and treating a patient having tumor lesions comprising administering a gene therapy retroviral vector particle comprising a mutated HSV-thymidine kinase (HSV-TK) polynucleotide

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND OF THE INVENTION Proliferative diseases, such as cancer, pose a serious challenge to society. Cancerous growths, including malignant cancerous growths, possess unique characteristics such as uncontrollable cell proliferation resulting in, for example, unregulated growth of malignant

Thymidine kinase TK1, peptide, corresponding antibodies and use of these in determination of tumor proliferation

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

TECHNICAL FIELD The present invention concerns a new cell growth related peptide and use thereof. More precisely, the invention serves as a marker for cell proliferation and this marker is a specific peptide sequence which is a part of the cellular enzyme thymidine kinase. This peptide can be used

Composition comprising interleukin-2 and thymidine kinase for the treatment of tumors

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for use in the treatment of tumors and the immunization of organisms against tumors. 2. Description of the Related Art It has been established very recently by various scientific teams that the

Radiation enhanced therapy for tumors expressing a gene for viral thymidine kinase in the presence of a 5-halogengated pyrimidine

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND OF THE INVENTION The present invention pertains to combination radiotherapy of tumors and more specifically to pharmaceutical compositions, and methods of treatment by gene therapy designed to sensitize tumors in animals, notably humans, and render them more susceptible to radiation, thus

Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines for the treatment of infections and cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

This application is a U.S. National Phase Application under 35 USC 371 of International Application PCT/SE2008/050268 filed Mar. 11, 2008, which claims priority from Swedish Application No. SE 0700649-7 filed Mar. 15, 2007, the entire disclosure of each of which is incorporated herein by

Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND Although efforts in cancer research have been ongoing for more than 20 years, cancer still accounts for more deaths than heart disease in persons younger than 85 years. Very little progress has been made in the past 30 years to decrease cancer mortality rates and incidence rates. In 2014,

Monoclonal antibodies to thymidine kinase 1 and uses in diagnostic and therapeutic applications

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

FIELD OF THE INVENTION The invention relates generally to a monoclonal antibody to thymidine kinase 1 useful for diagnosis, prognosis and treatment of cancer and certain blood disorders, and to prediction of recurrence in cancer patients. BACKGROUND OF THE INVENTION Once a cancer is detected, an

Oncolytic vaccinia virus combination cancer therapy

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

BACKGROUND OF THE INVENTION I. Field of the Invention The present invention relates generally to the fields of oncology and virology. More particularly, it concerns poxviruses, specifically including oncolytic vaccinia viruses suitable for the treatment of cancer and their use in combination with

Oncolytic vaccinia virus combination cancer therapy

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji

Ielogoties Reģistrēties

Iepriekšējais
1
2
3
4
Nākamais

Pievienojieties mūsu
facebook lapai

Herbal & Natural Medicine

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne

Darbojas 55 valodās
Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
Garšaugu atpazīšana pēc attēla
Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
Meklēt ārstniecības augus pēc to iedarbības
Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem

Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem